Bassem Chahine
Allergy & Immunology · Miami, FLNPI 1518971753
Payments from drug & device makers
Across 327 payments — averaging $28.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$845
- Regeneron Healthcare Solutions, Inc.$829
- Incyte Corporation$676
- Sanofi$601
- Pfizer$590
- plus $4K from 25 others
What the payments were for
- Consulting fees$250%
- Food & beverage$9,321100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 53 | $1,609 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $845 |
| Regeneron Healthcare Solutions, Inc. | 27 | $829 |
| Incyte Corporation | 29 | $676 |
| Sanofi | 18 | $601 |
| Pfizer | 27 | $590 |
| Galderma Laboratories, L.p. | 14 | $574 |
| Alk-abello, Inc | 25 | $475 |
| AstraZeneca | 12 | $464 |
| Genentech USA, Inc. | 14 | $359 |
| ADMA Biomanufacturing LLC | 3 | $349 |
| Optinose US, Inc. | 8 | $275 |
| Blueprint Medicines Corporation | 8 | $268 |
| Hikma Pharmaceuticals USA | 12 | $224 |
| Novartis | 8 | $203 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $185 |
| AbbVie | 6 | $143 |
| Amgen | 1 | $120 |
| Aimmune Therapeutics, Inc. | 4 | $99 |
| CSL Behring | 3 | $75 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| Lilly USA, LLC | 2 | $58 |
| LEO Pharma Inc. | 2 | $54 |
| Grifols USA, LLC | 2 | $47 |
| Pharming Healthcare, Inc. | 1 | $27 |
| Shire North American Group Inc | 2 | $24 |
| Organon | 3 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Octapharma USA, Inc. | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,347 in reported general payments places this provider in the 60th percentile of 204 allergy & immunology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,474 |
| Cromolyn Sodium | 14 | $3,780 |
| Levocetirizine Dihydrochloride | 15 | $785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,609 | $13,47421 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $23 | $3,78014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Miami
- Ileana RodicioMiami$3.8M
- Jose CarpioMiami$3.6M
- Nina RamirezMiami$833K
- Vicente ChavarriaMiami$828K
- Gary KleinerMiami$149K
- Neil GershmanMiami$18K
- Viviana SirvenMiami$14K
- Jaime LandmanAventura$3.9M
- Michael KohenDaytona Beach$3.6M
- Thomas CasaleTampa$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.